An Introduction to Pharmacovigilance by Patrick Waller(auth.)

By Patrick Waller(auth.)

Pharmacovigilance is the technology and actions on the subject of the detection, overview, realizing and prevention of inauspicious results or the other drug-related difficulties.

This introductory advisor is designed to help the swift realizing of the main rules of pharmacovigilance. Packed packed with examples illustrating drug questions of safety it not just covers the procedures concerned, however the regulatory elements and moral and societal issues of pharmacovigilance.

protecting the fundamentals step by step, this publication is ideal for novices and is key examining for these new to drug defense departments and pharmaceutical medication students.Content:
Chapter 1 what's Pharmacovigilance and the way has it constructed? (pages 1–14):
Chapter 2 simple strategies (pages 15–29):
Chapter three varieties and resources of knowledge (pages 30–43):
Chapter four the method of Pharmacovigilance (pages 44–60):
Chapter five Regulatory points of Pharmacovigilance (pages 61–73):
Chapter 6 foreign Collaboration (pages 74–79):
Chapter 7 moral and Societal concerns (pages 80–88):
Chapter eight destiny instructions (pages 89–93):
Chapter nine studying extra approximately Pharmacovigilance (pages 94–97):

Show description

Read or Download An Introduction to Pharmacovigilance PDF

Similar pharmacology books

Intelligent Drug Development: Trials and Errors in Clinical Research

Medical examine is seriously regulated and contains coordination of various pharmaceutical-related disciplines. each one person trial comprises contractual, regulatory, and ethics approval at every one website and in each one nation. scientific trials became so complicated and govt standards so stringent that researchers frequently strategy trials too carefully, confident that the method is sure to be insurmountably advanced and riddled with roadblocks.

Desk Reference of Clinical Pharmacology

Because the booklet of the bestselling first version of CRC table Reference of medical Pharmacology, dramatic discoveries in molecular drugs besides speedy technological advances have revolutionized the prognosis and ended in new drugs for use within the therapy of a huge variety of human illnesses.

Rules and Guidance for Pharmaceutical Manufacturers and Distributors

Familiarly often called the "Orange Guide," this identify is a vital reference paintings for all these interested by the manufacture or distribution of medications in or for Europe. it's compiled via the united kingdom drug regulatory physique, the MHRA, and brings jointly the eu and united kingdom tips records and data on laws on the subject of the manufacture and distribution of medications for human use.

Extra info for An Introduction to Pharmacovigilance

Example text

Any previous history of an ADR. Drug interactions occur when the presence of one drug affects the activity of another. This may occur either because both drugs act through the same pathway(s) – these are called ‘pharmacodynamic’ interactions – or through effects on absorption, distribution, metabolism or excretion – ‘pharmacokinetic’ interactions. The result may be an adverse reaction or modified effectiveness. g. an angiotensin converting enzyme (ACE) inhibitor plus a ‘potassium sparing’ diuretic may result in hyperkalaemia and cardiac arrhythmias].

The term ‘data mining’ is now widely used in this context, particularly in relation to systematic detection of signals from large spontaneous ADR databases. Processes for signal detection In the context of spontaneous ADR reporting, a signal is normally a series of cases of similar suspected ADRs reported in relation to a particular drug. g. aplastic anaemia, toxic epidermal necrolysis), a very small number of cases associated with a single drug is unlikely to be a chance phenomenon, even if the drug has been used quite widely.

Disease context is important because patients with more serious illnesses are much more likely to be prepared to accept potentially harmful treatments than those who have minor or self-limiting illnesses. g. a drug) with another (which could be any form of treatment or no treatment). I will return to this point in more detail in the section on risk-benefit balance below. Safety is a moving ball – there is a need to re-evaluate it as experience accumulates. Treatments previously considered acceptably safe may become ‘unsafe’ in the light of new evidence or the discovery of safer alternatives.

Download PDF sample

Rated 4.99 of 5 – based on 32 votes